Mr. Michael Frank reports
REVIVE THERAPEUTICS PROVIDES UPDATE OF NOVEL BUCILLAMINE FORMULATION DEVELOPMENT
Revive Therapeutics Ltd. has provided an update on the development of a next-generation lyophilized formulation of bucillamine.
Under an agreement with the University of Waterloo, formulation development is ongoing and aims to be completed by the end of December 2023. Discussions with contract development manufacturing organizations with expertise in the clinical manufacturing of lyophilized products are ongoing. The Company expects to have its novel lyophilized formulation of Bucillamine ready for clinical evaluation in 2024.
The Company intends to explore the novel Bucillamine formulation as a potential treatment for public health medical emergencies including, pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. In addition, as a potent antioxidant and anti-inflammatory, Bucillamine may be useful for orphan indications in rare inflammatory disorders such as ischemia-reperfusion injury resulting from solid organ transplantation.
The Company is committed to advancing the clinical and commercial development of Bucillamine through the following strategic initiatives:
Target Indications: Novel Bucillamine in an injectable version to expand on its potential therapeutic utility targeting rare disorders such as ischemia-reperfusion injury (i.e. organ transplantation), acute respiratory distress syndrome, and potential medical countermeasures, that may come with regulatory incentives awarded by the FDA, such as emergency use authorization, orphan drug, fast track, and breakthrough therapy designations.
Pharmaceutical Partnerships: Work with interested pharmaceutical partners to pursue potential domestic and international regulatory approvals and new clinical studies for infectious, inflammatory and respiratory disorders.
Government Support: Seek out potential funding and evaluation opportunities offered by, but not limited to, the Defence Research and Development Canada (DRDC) and the Biomedical Advanced Research and Development Authority (BARDA), the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS).
At this time, the Company will only provide regular updates via press releases as information becomes available.
About Revive Therapeutics Ltd.
Revive Therapeutics is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various programs. For more information, visit
We seek Safe Harbor.
© 2024 Canjex Publishing Ltd. All rights reserved.